| Site-selective protein-modification chemistry for basic biology and drug development N Krall, FP Da Cruz, O Boutureira, GJL Bernardes Nature chemistry 8 (2), 103-113, 2016 | 535 | 2016 |
| A small‐molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors N Krall, F Pretto, W Decurtins, GJL Bernardes, CT Supuran, D Neri Angewandte Chemie International Edition 53 (16), 4231-4235, 2014 | 299 | 2014 |
| Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation M Wichert, N Krall, W Decurtins, RM Franzini, F Pretto, P Schneider, ... Nature chemistry 7 (3), 241-249, 2015 | 203 | 2015 |
| Small targeted cytotoxics: current state and promises from DNA‐encoded chemical libraries N Krall, J Scheuermann, D Neri Angewandte Chemie International Edition 52 (5), 1384-1402, 2013 | 196 | 2013 |
| Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study B Snijder, GI Vladimer, N Krall, K Miura, AS Schmolke, C Kornauth, ... The Lancet Haematology 4 (12), e595-e606, 2017 | 169 | 2017 |
| Curative properties of noninternalizing antibody–drug conjugates based on maytansinoids E Perrino, M Steiner, N Krall, GJL Bernardes, F Pretto, G Casi, D Neri Cancer research 74 (9), 2569-2578, 2014 | 155 | 2014 |
| A bivalent small molecule-drug conjugate directed against carbonic anhydrase IX can elicit complete tumour regression in mice N Krall, F Pretto, D Neri Chemical Science 5 (9), 3640-3644, 2014 | 88 | 2014 |
| Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders C Kornauth, T Pemovska, GI Vladimer, G Bayer, M Bergmann, S Eder, ... Cancer discovery 12 (2), 372-387, 2022 | 85 | 2022 |
| Global survey of the immunomodulatory potential of common drugs GI Vladimer, B Snijder, N Krall, JW Bigenzahn, KVM Huber, CH Lardeau, ... Nature chemical biology 13 (6), 681-690, 2017 | 61 | 2017 |
| A 99mTc-labeled ligand of carbonic anhydrase IX selectively targets renal cell carcinoma in vivo N Krall, F Pretto, M Mattarella, C Müller, D Neri Journal of Nuclear Medicine 57 (6), 943-949, 2016 | 57 | 2016 |
| A comprehensive surface proteome analysis of myeloid leukemia cell lines for therapeutic antibody development V Strassberger, KL Gutbrodt, N Krall, C Roesli, H Takizawa, MG Manz, ... Journal of proteomics 99, 138-151, 2014 | 41 | 2014 |
| Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL C Schmidl, GI Vladimer, AF Rendeiro, S Schnabl, T Krausgruber, ... Nature chemical biology 15 (3), 232-240, 2019 | 39 | 2019 |
| Targeting carbonic anhydrase IX with small organic ligands M Wichert, N Krall Current opinion in chemical biology 26, 48-54, 2015 | 38 | 2015 |
| Tumor-Targeting Antibody–Anticalin Fusion Proteins for in Vivo Pretargeting Applications M Steiner, K Gutbrodt, N Krall, D Neri Bioconjugate chemistry 24 (2), 234-241, 2013 | 31 | 2013 |
| A microdosing study with 99mTc-PHC-102 for the SPECT/CT imaging of primary and metastatic lesions in renal cell carcinoma patients OC Kulterer, S Pfaff, W Wadsak, N Garstka, M Remzi, C Vraka, L Nics, ... Journal of Nuclear Medicine 62 (3), 360-365, 2021 | 26 | 2021 |
| Entwicklung zielgerichteter niedermolekularer zytotoxischer Wirkstoffverbindungen mit DNA‐codierten chemischen Bibliotheken N Krall, J Scheuermann, D Neri Angewandte Chemie 125 (5), 1424-1443, 2013 | 26 | 2013 |
| Patient-derived model systems and the development of next-generation anticancer therapeutics N Krall, G Superti-Furga, GI Vladimer Current Opinion in Chemical Biology 56, 72-78, 2020 | 12 | 2020 |
| Ein niedermolekulares Ligand‐Wirkstoff‐Konjugat zur Behandlung von Carboanhydrase IX exprimierenden Tumoren N Krall, F Pretto, W Decurtins, GJL Bernardes, CT Supuran, D Neri Angewandte Chemie 126 (16), 4315-4320, 2014 | 9 | 2014 |
| (In) organic anions as carbonic anhydrase inhibitors N Krall, F Pretto, W Decurtins, SU Rehman, ZH Chohan, F Gulnaz, ... Angew Chem Int Ed Engl 53, 4231-5, 2014 | 7 | 2014 |
| Selective inhibition of Bruton’s tyrosine kinase by a designed covalent ligand leads to potent therapeutic efficacy in blood cancers relative to clinically used inhibitors BB Sousa, CR de Almeida, AF Barahona, R Lopes, A Martins-Logrado, ... ACS Pharmacology & Translational Science 5 (11), 1156-1168, 2022 | 3 | 2022 |
